These modifications influence cancer cell survival strategies by regulating pathways such as PD‐L1/PD‐1 and mTOR/AKT, as well as the immune microenvironment (e.g., CD8+ T cell infiltration and Treg cells), which presents new possibilities for cancer immunotherapies. This evidence concerns the gene PDCD1 and cancer.